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Abstract
Hepatitis C virus (HCV) infection is a prominent cause of
chronic liver disease and may lead to serious complications
such as liver failure and need for a transplant. The virus is
transmitted via exposure to blood and is classified into various genotypes based on genetic mutations in the virus. Current treatment options for HCV infection are not effective in
all patients, and there are limited options for patients infected with a genotype other than genotype 1. Two new
medications have been approved recently for treatment of
HCV infection. Simeprevir (Olysio®) gained U.S. Food and
Drug Administration (FDA) approval in November 2013, and
sofosbuvir (Sovaldi®) was approved in December 2013. Information from clinical trials with each of the medications
supports their safety and efficacy in appropriate patient
populations. The adverse effects are generally tolerable;
however, for some patients, the adverse effects, drug interactions and cost can be limiting factors.

Introduction
Hepatitis C virus is a blood-borne pathogen leading to longterm hepatic complications if not properly treated.1 Current
therapy for HCV includes ribavirin (RBV), peg-interferon alfa
(PeglFN) and two options for protease inhibitors (boceprevir
and telaprevir), which can only be used in one genotype of
HCV infection.2-4 Two new medications were recently approved for treatment of chronic HCV infection: simeprevir
(Olysio®) in November 2013 and sofosbuvir (Sovaldi®) in
December 2013.s,6 These new medications can provide more
treatment options to patients with different genotypes or for
whom prior treatment with RBV and PeglFN was unsuccessfuJ.7,8 Safety and efficacy have been demonstrated in several
clinical trials.9-12 The adverse reactions and cost of these
medications are important factors to consider when determining treatment for HCV infection in a patient.
Disease State Overview
Hepatitis C infects approximately 170 million individuals
worldwide, which has become both a public health and an
economic issue.13 Being the most common blood-borne
pathogen, the HCV is one of the leading causes of chronic
liver disease and the third leading cause of death in patients
with end stage renal disease,1.2 All individuals who are
infected with HCV are at a greater risk for developing longterm complications such as cirrhosis, liver failure and hepatocellular carcinoma.14
Hepatitis C virus is a single-stranded, positive RNA virus,
which has a high rate of mutation, leading to therapy resisJuly 2014 Volume 5, Issue 3

tance and immune system evasion.ls Presentation varies
from patient to patient in that some patients may present
with mild hepatitis or inflammation of the liver, while others
experience scarring or even liver cancer.16 The first phase
begins with HCV exposure which results in high viral titers
being expressed in the blood. In this early stage, which typically lasts six to eight weeks, a T-cell mediated immune
response is apparent in the absence of liver damage. The second phase of HCV infection begins with the generation of
HCV specific antibodies and T-cells. This phase is also characterized by an increase in liver enzyme levels, which is evidence of hepatocyte destruction. Phase three, which takes
place 12 to 24 weeks after infection, shows variations in HCV
viremia as well as decreasing capabilities of functional
T-cells. Phase four, or 24 weeks post-infection, marks the end
of the acute phase of the HCV infection as cellular immunity
continues to evolve.
The virus itself does not cause damage to the liver, but rather
the response it elicits from the immune system causes
healthy liver tissue to be replaced with scar tissue.10 Typically, the preferred treatment for HCV is PegIFN along with
RBV, a nucleoside analogue, to which approximately 55 percent of patients respond. For those patients who are nonresponders, few treatment options exist, which has led to
further research and development of HCV medications.
Treatment for HCV has evolved over the past years owing to
advances in research and drug therapy.2 Treatment in the
mid-1990s consisted of interferon monotherapy, which was
injected three times a week for a total duration of six to 12
months. In the late 1990s, RBV was added to interferon,
which dramatically increased a patient's sustained virologic
response (SVR). A sustained virologic response is defined as
a lack of HCV in the blood after 24 weeks of treatment and
remains the best indication of how successful therapy is in a
patient.18 Therapy evolved once more to the current regimen
of PegIFN in addition to RBV.2The ultimate goal of treatment
in patients with HCV is to reach an SVR, as defined above.
Currently, there is no vaccine to prevent HCV.19
Genotyping plays an important role in determining treatment for HCv.20 Currently, there are six clinically significant
genotypes (1-6) identified for HCV, of which some are found
to be more prevalent in different parts of the world. For example, genotypes 1 through 3 are more common in the
United States and Europe, genotype 4 is found most often in
Egypt, and genotype 6 is more common in South Asia. Based
on what genotype a person has, treatment and also response
to treatment will differ. HCV genotyping is done to provide
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the most effective therapy and to get the maximum response
out of the medication prescribed.

Overview of New Medications
Two new medications have recently been approved for the
treatment of chronic HCV infection.6 The first is simeprevir
(Olysio®), approved Nov. 22, 2013. 5 The second is sofosbuvir
(Sovaldi®), approved Dec. 6, 2013.
Simeprevir is a HCV NS3/4A protease inhibitor to be used in
combination with Peg!FN and RBV to treat chronic HCV infection in patients with genotype 1 HCV infection.7 The HCV
NS3/4A protein is a serine protease that is essential in cleaving the single HCV polyprotein precursor into the 10 individual proteins needed for HCV maturation and replication.21,22
Inhibition of NS3/4A prevents the viral replication of HCv.21
Simeprevir is the third HCV NS3/4A protease inhibitor to
receive approval, with the previous two being boceprevir
(Victrelis®) and telaprevir (Incivek®), each approved in
2011.5 Simeprevir differs from the other two protease inhibitors in that it is administered only once daily; however, all
three protease inhibitors are only effective in genotype 1
HCV infection and must be used with both Peg!FN and
RBV.3.4.7 Simeprevir is a 150 mg capsule taken once daily
with food.7 The treatment schedule is 12 weeks of simeprevir
with Peg!FN and RBV for 24 or 48 weeks, depending on prior
treatment status.
Sofosbuvir is a NS5B polymerase inhibitor. 8 The HCV protein
NS5B is an RNA polymerase that transcribes viral RNA in
order to produce HCV proteins.s,23 Sofosbuvir is a nucleotide
prodrug that is converted in the liver to a uridine analog,
which then inhibits the work of NS5B by incorporating into
HCV RNA and acting as a chain terminator, thereby preventing the completion of viral replication. Sofosbuvir has shown
efficacy in treating genotypes 1, 2, 3 and 4 HCV infection.a
Sofosbuvir is a 400 mg tablet taken once daily without regard
to food. Genotype of HCV infection determines treatment
duration and PegIFN requirement. Genotype 1 is treated with
sofosbuvir plus Peg!FN and RBV for 12 weeks, or if ineligible
for PegIFN, sofosbuvir plus RBV for 24 weeks. Genotype 2 is
treated with sofosbuvir plus RBV for 12 weeks, and genotype
3 has the same treatment extended to 24 weeks. Genotype 4
is treated with sofosbuvir plus Peg!FN and RBV for 12 weeks.
Sofosbuvir is the first drug in its class and the first drug that
does not necessarily require concomitant use of Peg!FN for
the treatment of chronic HCV infection.6
Review of Clinical Trials
Several clinical trials have evaluated the safety and efficacy
of these two new medications. One of the clinical trials evaluated by the FDA in considering the approval of simeprevir
was the ASPIRE triaJ.10 ASPIRE was a phase Ilb, randomized,
double-blind trial. This trial evaluated the safety and efficacy
of simeprevir plus Peg!FN/RBV in comparison to PegIFN/
RBV alone in patients with HCV genotype 1 who have previously failed to respond to treatment with PeglFN/RBV. Four
hundred sixty-two patients began the trial and were divided
into seven groups. All groups received Peg!FN/RBV for 48
weeks. Each group also received either 100 mg or 150 mg
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simeprevir once daily for 12, 24 or 48 weeks, or no simeprevir, designated as the control group. The primary end point
of the study was the proportion of patients maintaining SVR
at 24 weeks after end of treatment (SVR24). In the simeprevir groups, 60.6 to 80.0 percent of patients achieved SVR24
compared to 22.7 percent of the control group, demonstrating efficacy of the addition of simeprevir over Peg!FN/RBV
alone. In the 150 mg simeprevir groups, 72.9 percent of patients achieved SVR24 compared to 65.6 percent of patients
in 100 mg simeprevir groups, supporting the choice of
150 mg capsules. Duration of treatment with simeprevir
showed no improvement in SVR24 rate beyond 12 weeks
(68.2% in 12-week groups, 69.2% in 24-week groups and
70.2% in 48-week groups) supporting the use of simeprevir
for only 12 weeks.
The ASPIRE trial further looked at the efficacy of simeprevir
versus the control group in patients with prior null response,
prior partial response and relapse to previous treatment
with Peg!FN/RBV.10 In prior null response patients (patients
that did not achieve SVR in previous treatment with PegIFN/
RBV), SVR24 rates were 37.5 to 58.8 percent in simeprevir
groups versus 18.8 percent in control group. In prior partial
response patients (patients that had reduced HCV RNA in
previous treatment with Peg!FN/RBV but did not achieve
SVR), SVR24 rates were 47.8 to 86.4 percent in simeprevir
groups versus 8.7 percent in control group. In prior relapse
patients (patients that achieved SVR at end of treatment
(EOT) with Peg!FN/RBV but had detectable HCV RNA 24
weeks later), SVR24 rates were 76.9 to 88.9 percent in
simeprevir groups versus 37 percent in control group. This
indicates potential efficacy in patients with prior treatment
failure. The safety profile in simeprevir groups was similar to
that of the control group (Peg!FN/RBV alone). All groups had
similar total incidence of adverse events (AEs) and severe
AEs, with fatigue, headache, pruritus, influenza-like illness
and neutropenia most frequently reported. Groups treated
with simeprevir had higher frequency of rash (26.5% versus
18.2%) and pruritus (34.1% versus 16.7%) than Peg!FN/
RBV groups, although severity of these AEs was similar.
Another clinical trial evaluating simeprevir was the PILLAR
trial. 11 PILLAR was a phase Ilb, randomized, double-blind
trial that assessed the safety and efficacy of simeprevir plus
Peg!FN/RBV in comparison to Peg!FN/RBV alone in treatment-na'ive patients with HCV genotype 1. The trial began
with 386 patients divided into five groups. All groups
received Peg!FN/RBV for 48 weeks unless the patient was
eligible to end all treatment at 24 weeks. Each group also
received either 75 mg or 150 mg simeprevir once daily for 12
or 24 weeks, or no simeprevir, designated as the control
group. If a simeprevir-treated patient achieved rapid virologic response (RVR; defined by HCV RNA undetectable at
week 4) and had undetectable HCV RNA at weeks 12, 16 and
20, Peg!FN/RBV could be stopped at week 24 rather than
finishing the full 48 weeks. The primary end point was the
proportion of patients maintaining SVR at week 72 of the
trial (SVR72), with treatment ending at week 48 or earlier.
There was a statistically significant difference in SVR72 between the 150 mg, 12-week simeprevir group versus control
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group (77.9% versus 64.9%, P<0.05) and between the 150
mg, 24-week simeprevir group versus control group (84.8%
versus 64.9%, p<0.05), indicating that the addition of 150 mg
daily simeprevir leads to greater success in therapy than
PegIFN/RBV alone. No differences in SVR rates were noted
between different durations of simeprevir treatment. RVR
was achieved by 68.0 to 75.6 percent of simeprevir patients
versus 5.2 percent of patients in the control group. Of simeprevir-treated patients, 79.2 to 86.1 percent were eligible to
complete all treatment at week 24. This is significant because
it allowed these patients to cut treatment duration in half,
saving money, time and inconvenience. Adverse events and
serious AEs were similar across all groups. The most frequently reported AEs were fatigue, influenza-like illness, pruritus, headache and nausea, typically associated with
PegIFN/RBV therapy. This trial did not show higher frequency of rash and pruritus in simeprevir groups compared
to PegIFN/RBValone.
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group. At EOT (12 weeks prior to this measurement), 100
percent of sofosbuvir/RBV group versus 0 percent of RBV
group had achieved SVR. This difference in SVR in the sofosbuvir/RBV group was due to viral relapse after EOT. All cases
of relapse that were reported occurred within 12 weeks after
EOT, with no new cases ofrelapse reported between 12 to 24
weeks after EOT. Treatment with sofosbuvir/RBV led to
SVR12 in 93 percent of patients with HCV genotype 2 versus
61 percent of patients with HCV genotype 3. Adverse events
occurred more frequently in the sofosbuvir /RBV group than
the RBV group, particularly fatigue, insomnia and anemia.
The rate of AEs was overall low in both groups. The rate of
serious AEs was similar between the two groups. Although
the use of RBV alone is not a valid treatment option for the
treatment of chronic HCV, giving the impression that this
study is invalid, treatment with RBV alone may be the only
option for patients who cannot tolerate PegIFN, especially in
patients with non-genotype 1 HCV infection. This study supports the idea that treatment with sofosbuvir /RBV has better
efficacy for patients with genotype 2 and 3 than RBV alone.9

The FDA approval of the other new HCV treatment medication, sofosbuvir, was dependent on the FISSION trial and the
POSITRON trial, among others.9,12 The FISSION trial was a
phase III, randomized, open-label triaJ.12 This study evaluated
the safety and efficacy of sofosbuvir plus RBV in comparison
to PegIFN/RBV alone in treatment-naive patients with HCV
genotype 2 or 3. At the beginning of the trial, 499 patients
were randomized to receive either 400 mg sofosbuvir once
daily plus RBV for 12 weeks or to receive Peg!FN/RBV for 24
weeks. The primary end point was defined as the proportion
of patients maintaining SVR at 12 weeks after EOT (SVR12).
The primary end point was achieved in 67 percent of patients in the sofosbuvir/RBV group versus 67 percent in the
PegIFN/RBV group, indicating that sofosbuvir/RBV therapy
is not inferior in efficacy to PegIFN/RBV therapy. This is significant in that it allows patients the option to receive treatment with only oral medications. Patients with genotype 2
achieved SVR12 in 97 percent of sofosbuvir/RBV group versus 78 percent of PegIFN/RBV group, supporting the efficacy
of sofosbuvir/RBV therapy in genotype 2 HCV. Patients with
genotype 3 HCV achieved SVR12 in 56 percent of sofosbuvir/
RBV group versus 63 percent of PegIFN/RBV group, indicating sofosbuvir/RBV for 12 weeks is not as effective as
Peg!FN/RBV for 24 weeks in these patients. The FDA recommends using sofosbuvir/RBV for 24 weeks (not 12 weeks) in
patients with genotype 3.a Adverse events in this trial occurred more frequently in PegIFN/RBV group than the sofosbuvir/RBV group, and serious AEs were low among all
groups. The most common AEs in all groups were fatigue,
headache, nausea and insomnia.12

There are two major AEs with simeprevir: teratogenicity and
sun sensitivity. Male and female patients taking simeprevir
with RBV must use two forms of birth control while on the
therapy and for six months after discontinuation.24 Female
patients must be monitored monthly via pregnancy tests.
Severe rashes may develop with simeprevir. These rashes
occur with sun exposure and usually develop within the first
four weeks of treatment. Patients should be encouraged to
contact a health care provider if any sort of redness, rash or
conjunctivitis occurs. Severe cases may require hospitalization, so patients should be urged to wear sunscreen and protective clothing (such as hats) if they are going to be outside
for long periods of time. As it contains a sulfonamide moiety,
simeprevir should be used with caution in those patients
with sulfa allergies. Simeprevir is contraindicated with various medications ranging from over-the-counter supplements
such as St. John's Wort to prescription hypertension medications. Patients should provide health care providers with a
complete drug list, and pharmacists should monitor use of
these contraindicated medications in patients taking simeprevir.

Another clinical trial used by the FDA in consideration of sofosbuvir was the POSITRON trial. 9 POSITRON was a phase III,
randomized, double-blinded trial. This trial evaluated the
safety and efficacy of sofosbuvir /RBV compared to RBV
alone in patients with HCV genotype 2 or 3 unable to take
PegIFN. The trial began with 278 patients randomized to
receive RBV and sofosbuvir 400 mg once daily for 12 weeks
or to receive RBV and placebo for 12 weeks. The primary end
point was SVR12. The primary end point was achieved in 78
percent of sofosbuvir/RBV group versus 0 percent of RBV

Similar to simeprevir, sofosbuvir requires two forms of birth
control and pregnancy monitoring due to use with RBV,
along with two negative pregnancy tests prior to beginning
therapy. 7 Other sofosbuvir side effects include central nervous system effects such as depression, insomnia and nausea
with headache and fatigue being the most common. Abnormalities in lab values including bilirubin, creatinine kinase,
and lipases were also seen in patients taking sofosbuvir. The
main drug interaction involved in sofosbuvir use is seen in
potent intestinal P-glycoprotein inducers such as St. John's
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Pharmacists' Impact
A look at the new medications' AEs and drug interactions can
help a health care provider decide if these new medications
would be right for his or her patient. Pharmacists can help
counsel on the new drugs' adverse reactions, helping to ensure a safe introduction of these new medications.
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Wort or rifampicin. These medications can alter the concentrations of sofosbuvir; therefore, their concurrent use is discouraged.
Neither of the medications has recommended renal or hepatic dosing adjustments at this time, due to insufficient evidence in these patient populations,7.B Each therapy is to be
given over 12 weeks (with the exception of sofosbuvir in
genotype 3), while monitoring different levels for dosing adjustments. Hemoglobin levels should be monitored with use
of sofosbuvir due to ribavirin co-administration.a In patients
with no history of cardiac disease, it is recommended that
ribavirin be reduced to 600 mg/day with hemoglobin levels
less than 10 g/dL and discontinued with levels less than
8.5 g/dL. In patients with a history of stable cardiac disease,
ribavirin levels should be reduced with any drop in hemoglobin levels of over 2 g/dL over a four-week period or discontinued if hemoglobin levels drop below 12 g/dL. Hepatitis C
virus RNA levels are monitored with use of simeprevir.2s It is
recommended to discontinue simeprevir, as well as Peg!FN
and RBV, if HCV RNA levels reach 25 IU/mL or greater at any
point during the therapy duration.
Cost should be considered when weighing risks versus benefits of these therapies. Both therapies have gained media attention for their cost, many noting that these medications
should be saved for those with severe cases of hepatitis c .26
Simeprevir's 12 week therapy runs at $66,360, while sofosbuvir is priced at $84,000.21,2a

Place in Therapy
The American Association for the Study of Liver Diseases
(AASLD) provides working guidelines for the treatment of
HCV infection that expound upon the place in therapy for
these two new medications.2 9 Because these medications
were approved relatively recently, the AASLD has created
web-based 2014 guidelines that are continuously being
modified as new data become available. In general, the
AASLD 2014 guidelines recommend the use of sofosbuvir
with RBV as first-line treatment in nearly all patients
(treatment-naive and treatment-experienced patients with
genotype 1 through 6), also including Peg!FN when appropriate. The guidelines find sofosbuvir with RBV to have the best
balance of high efficacy and AEs. Simeprevir with RBV /
PegIFN is listed by the AASLD as an alternative regimen for
treating genotype 1 and 4 (despite lack of FDA approval for
use in genotype 4). The AASLD guidelines no longer recommend the use RBV /PegIFN alone for nearly all patients,
claiming that therapy with RBV/Peg!FN alone is inferior to
the addition of sofosbuvir or simeprevir, due to lower efficacy, higher rate of serious AEs, and longer treatment duration when RBV /Peg!FN is used alone. The guidelines prefer
simeprevir over telaprevir and boceprevir, claiming comparatively lower efficacy, lower tolerability, and higher pill
burden for telaprevir and boceprevir. Sofosbuvir and simeprevir may be used more prominently for the treatment of
HCV infection as these guidelines are finalized.
Conclusion
Hepatitis C virus is one of the most common blood-borne
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pathogens and can lead to serious long-term complications. 1
Simeprevir and sofosbuvir have been shown to be effective
and safe in multiple studies for the treatment of chronic HCV
infection in both treatment-naive and treatment-experienced
patients.7,8 Simeprevir is approved for the treatment of genotype 1 HCV and requires concurrent RBV and PeglFN.7 Sofosbuvir can treat genotype 1 through 4 HCV with concurrent
RBV and sometimes PegIFN.a The side effect profile, drug
interactions and cost of each of these new medications must
be weighed against the potential benefit to the patient in
treating chronic HCV infection.
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